🇺🇸 FDA
Pipeline program

mRNA-4157, BCG VACCINE

V940-011

Phase 2 small_molecule active

Quick answer

mRNA-4157, BCG VACCINE for Bladder cancer is a Phase 2 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck Sharp and Dohme
Indication
Bladder cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials